tuneTypical Dose
No evidence-based generic sea moss dose exists because products vary substantially in species, processing, and iodine content
Supplement
Sea Moss
Chondrus crispus
Evidence TierDWADA NOT PROHIBITED
watchEffect Window
Any effect is more likely to reflect iodine exposure than a validated supplement response. Monitor thyroid-related symptoms rather than expecting a defined benefit window.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Sea moss is mostly an unstandardized seaweed source of iodine and other minerals, not an evidence-backed supplement for immunity, thyroid support, libido, or skin.
Sea moss is marketed as a mineral-rich superfood that supports immunity, thyroid health, gut health, skin, energy, and even sexual function. The problem is that there is very little direct human efficacy evidence for those claims. What the literature does support is something more basic and less flattering. Sea moss can provide meaningful, bioavailable iodine, and commercial seaweed products often have variable or poorly disclosed iodine content. That makes thyroid risk and dose uncertainty more important than the wellness marketing.
Sea moss is mainly a source of iodine and other seaweed-derived constituents rather than a well-defined therapeutic mechanism. The most clinically relevant mechanism is that iodine from Chondrus crispus can be bioavailable enough to alter thyroid exposure, while the marketed immunity or vitality mechanisms remain largely speculative in humans.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- No direct human evidence supports the main marketed wellness claims for generic sea moss
- Sea moss can materially increase iodine exposure
Secondary Outcomes
- Product iodine content is highly variable across commercial seaweed products
- Thyroid dysfunction risk is more evidence based than benefit claims
Safety
Contraindications and Interactions
Contraindications
- Hyperthyroidism or Graves disease
- Thyroid nodules or thyroid autonomy
- Hashimoto thyroiditis or unstable thyroid disease
- Pregnancy
Side effects
- Excessive iodine exposure
- Thyroid dysfunction
- Mild GI upset
Interactions
- Levothyroxine or thyroid-medication titration
- Antithyroid medications
Avoid if
- You have hyperthyroidism, Graves disease, thyroid nodules, or poorly controlled thyroid disease
- You are using sea moss as a generic thyroid-support supplement without known iodine content
- You cannot verify the species or iodine disclosure on the product
Evidence
Study-level References
sm-SRC-001Human feeding and observational study
Sourceopen_in_newAndersen S, Noahsen P, Rex KF, et al. Iodine in Edible Seaweed, Its Absorption, Dietary Use, and Relation to Iodine Nutrition in Arctic People. J Med Food. 2019;22(4):421-426. doi:10.1089/jmf.2018.0187. PMID:30990756.
Population: Eight adults in an acute seaweed-ingestion substudy plus community-based Inuit participants aged 50 to 69 years in Greenland.
Dose protocol: 45 g edible seaweed in the acute ingestion substudy
Key findings: Chondrus crispus contributed substantial bioavailable iodine and seaweed intake was associated with higher iodine excretion.
Notes: Useful because it shows exposure, not because it proves a wellness benefit.
Paper content
This human feeding and observational paper is useful for sea moss because it shows that Chondrus crispus can deliver substantial, bioavailable iodine rather than acting like an inert plant powder. The study does not show a wellness or thyroid-support benefit. It shows that edible seaweed intake materially changes iodine exposure and therefore deserves cautious dosing and thyroid-risk framing.
sm-SRC-002Risk assessment study
Sourceopen_in_newDarias-Rosales J, Rubio C, Gutiérrez ÁJ, et al. Risk assessment of iodine intake from the consumption of red seaweeds (Palmaria palmata and Chondrus crispus). Environ Sci Pollut Res Int. 2020;27(36):45737-45741. doi:10.1007/s11356-020-10478-9. PMID:32803579.
Population: Thirty retail samples of red seaweeds, including Irish moss (Chondrus crispus) and dulse.
Dose protocol: Exposure modeling for dehydrated Irish moss, including 4 g/day and larger intake scenarios
Key findings: Irish moss contributes meaningful iodine exposure and safety depends on serving size and concentration.
Notes: Specific to Chondrus crispus, but this is a risk assessment rather than a clinical outcome trial.
Paper content
This paper is narrower than a clinical trial, but it matters because it specifically models iodine exposure from Chondrus crispus. The main point is not that Irish moss is dangerous at any intake. The main point is that it is an iodine-containing seaweed whose exposure profile depends heavily on concentration and serving size, so supplement marketing that ignores iodine content is incomplete.
sm-SRC-003Market survey and laboratory analysis
Sourceopen_in_newAakre I, Solli DD, Markhus MW, et al. Commercially available kelp and seaweed products - valuable iodine source or risk of excess intake? Food Nutr Res. 2021;65:7584. doi:10.29219/fnr.v65.7584. PMID:33889064.
Population: Ninety-six commercially available macroalgae products from the Norwegian market, including whole foods, foods containing seaweed, and dietary supplements.
Dose protocol: Commercial product portions and labeled daily doses across 96 macroalgae products
Key findings: Many macroalgae products could exceed the iodine upper limit in one serving or dose, with poor labeling in some cases.
Notes: Strong real-world reason not to treat sea moss as a standardized supplement.
Paper content
This market-analysis paper is one of the most useful real-world safety sources for sea moss-like products because it shows just how variable iodine exposure can be across commercial macroalgae foods and supplements. Many products could exceed the iodine upper limit in a single labeled portion or dose, and species labeling was sometimes inadequate or inaccurate. That supports a conservative approach to any supplement sold simply as sea moss.
sm-SRC-004Case report
Sourceopen_in_newKhalifa M, Aftab HB, Kantorovich V. Fueling the Fire: Irish Sea-Moss Resulting in Jod-Basedow Phenomenon in a Patient With Grave's Disease. J Endocr Soc. 2021;5(Suppl 1):A906. doi:10.1210/jendso/bvab048.1849. PMCID:PMC8090171.
Population: A 28-year-old woman with underlying Graves disease and intermittent use of store-bought Irish sea moss and bladderwrack supplements.
Dose protocol: Intermittent store-bought Irish sea moss and bladderwrack use over about 2 years
Key findings: Thyrotoxicosis improved after sea moss discontinuation in a patient with underlying Graves disease.
Notes: Directly relevant safety case, but only a single-patient report.
Paper content
This is only a case report, but it is directly relevant because it ties Irish sea moss supplement use to clinically important iodine-triggered thyrotoxicosis in a person with Graves disease. It should not be used to imply that sea moss predictably causes thyroid storm in healthy people. It should be used to justify explicit thyroid-disease contraindications and a warning that marketed high-iodine seaweed products are not benign in susceptible users.
sm-SRC-005Randomized, double-blind, cross-over trial.
Sourceopen_in_newWagner R, Buettner J, Heni M, et al. Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial. BMC Med. 2024;22:571. doi:10.1186/s12916-024-03771-8. PMID:39593091.
Population: Healthy male adults.
Dose protocol: Randomized double-blind crossover trial of carrageenan (a major sea moss polysaccharide) in 20 healthy men.
Key findings: Examined whether dietary carrageenan from red seaweed affects insulin sensitivity. Provides human metabolic data on a key sea moss constituent.
Notes: Tests carrageenan (a Chondrus crispus polysaccharide) rather than whole sea moss. Published in BMC Medicine with rigorous crossover design.
Paper content
This randomized double-blind crossover trial examined carrageenan, a polysaccharide derived from red seaweeds including Chondrus crispus (sea moss), and its effects on insulin sensitivity in 20 healthy men. Carrageenan is widely used as a food additive and is present in sea moss products. The study investigated whether carrageenan exposure could induce insulin resistance, as suggested by preclinical models. This is relevant to sea moss users because carrageenan is a major bioactive component of Chondrus crispus. The findings provide human metabolic data about a key sea moss constituent, moving beyond the compositional and iodine-exposure studies that previously characterized sea moss evidence. Published in BMC Medicine, this is a well-designed trial with a rigorous crossover methodology.